Millendo Therapeutics
Clinical-stage biotechnology company developing oral small-molecule therapeutics for oncology. Research emphasis is on agents that directly kill tumor cells and modulate the tumor microenvironment to enhance anti-tumor immunity. The company has advanced programs through Phase 1 and Phase 1b/2 studies and presents preclinical and clinical data at major cancer conferences.
Industries
Nr. of Employees
small (1-50)
Millendo Therapeutics
Products
Oral PPAR antagonist (clinical-stage)
Clinical-stage small-molecule antagonist of PPAR designed to inhibit fatty acid oxidation and modulate the tumor microenvironment to stimulate tumor-specific immunity; demonstrated preclinical tumor growth inhibition and increased tumor-infiltrating CD8+ T cells and has reported randomized Phase 1b/2 combination data in hepatocellular carcinoma.
Oral EP2/EP4 dual antagonist (clinical-stage)
Orally bioavailable dual antagonist of EP2 and EP4 prostaglandin receptors intended to abrogate PGE2-driven tumor growth and immune suppression; preclinical data show potency and survival benefits in mouse models and the program has completed monotherapy dose escalation.
Oral PPAR antagonist (clinical-stage)
Clinical-stage small-molecule antagonist of PPAR designed to inhibit fatty acid oxidation and modulate the tumor microenvironment to stimulate tumor-specific immunity; demonstrated preclinical tumor growth inhibition and increased tumor-infiltrating CD8+ T cells and has reported randomized Phase 1b/2 combination data in hepatocellular carcinoma.
Oral EP2/EP4 dual antagonist (clinical-stage)
Orally bioavailable dual antagonist of EP2 and EP4 prostaglandin receptors intended to abrogate PGE2-driven tumor growth and immune suppression; preclinical data show potency and survival benefits in mouse models and the program has completed monotherapy dose escalation.
Expertise Areas
- Immuno-oncology drug discovery
- Small-molecule oncology therapeutics
- Translational research and preclinical models
- Structure-based drug design
Key Technologies
- PPAR antagonism
- EP2/EP4 receptor antagonism
- X-ray crystallography (co-crystals)
- CHO cell-based luciferase reporter assays
News & Updates
Participation and webcast presentation at the Piper Sandler healthcare conference.
Webcast and presentation materials for a global randomized Phase 1b/2 combination study update.
AACR conference poster presenting mechanism-of-action data for a PPARα antagonist program.
Preclinical poster presented at AACR describing PPARα antagonist data.
Oral presentation of Phase 1 data at ASCO and release of positive randomized Phase 1b/2 combination data in hepatocellular carcinoma.
Participation and webcast presentation at the Piper Sandler healthcare conference.
Webcast and presentation materials for a global randomized Phase 1b/2 combination study update.
AACR conference poster presenting mechanism-of-action data for a PPARα antagonist program.
Preclinical poster presented at AACR describing PPARα antagonist data.
Oral presentation of Phase 1 data at ASCO and release of positive randomized Phase 1b/2 combination data in hepatocellular carcinoma.